成人伴发疾病的呼吸道合胞病毒：流行病学、疫苗和治疗方法的最新进展。
Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments.
机构信息
Université Paris Cité, INSERM UMR1137, IAME, F-75018, Paris, France; AP-HP Nord, Emergency Department, Bichat-Claude Bernard University Hospital, Paris, France.
Laboratoire Cerba, Infectious Diseases Department, Saint Ouen l'Aumône, France.
出版信息
Clin Microbiol Infect. 2023 Dec;29(12):1538-1550. doi: 10.1016/j.cmi.2023.08.028. Epub 2023 Sep 2.
BACKGROUND
Respiratory syncytial virus (RSV) is widely known as a frequent cause of respiratory distress among adults, particularly in older people. Recent years have witnessed several improvements in respiratory virus detection, leading to more questions about therapeutic management strategies.
OBJECTIVES
This narrative review focuses on the RSV burden in older people and adults with risk factors and provides an update on the main recent developments regarding managing this infection.
SOURCES
A comprehensive PubMed search was conducted till August 2023 to identify studies on RSV among the adult population. We included observational studies, RCTs on vaccines, and different therapies.
CONTENT
This review should give clinicians an overview of RSV epidemiology and burden among older people and adults with pre-existing risk factors, the most recent randomized clinical trials on RSV vaccines, and the existing data on the different therapeutics existing and under development.
IMPLICATIONS
There is a growing body of evidence on RSV burden in adults. The landscape of preventive and curative treatments is quickly evolving.
背景
呼吸道合胞病毒（RSV）是一种广为人知的呼吸道疾病病原体，尤其在老年人中更为常见。近年来，呼吸道病毒检测技术得到了显著改进，这也引发了人们对治疗管理策略的更多疑问。
目的
本综述聚焦于具有危险因素的老年人和成年人中的 RSV 负担，并就该感染的主要最新进展提供了更新信息。
资料来源
截至 2023 年 8 月，我们通过全面的 PubMed 搜索，以确定针对成年人群体的 RSV 研究。我们纳入了观察性研究、疫苗的 RCT 以及不同的治疗方法。
内容
本综述旨在为临床医生提供有关老年人和具有潜在危险因素的成年人群体中 RSV 流行病学和负担的概述、最新的 RSV 疫苗随机临床试验结果，以及现有和正在开发的不同治疗方法的数据。
意义
目前有关成年人 RSV 负担的证据不断增加。预防和治疗手段的领域正在迅速发展。
Zotero 插件